Biohaven fails phase 3 SMA test but plans talks with FDA, plots move into obesity

A phase 3 trial of Biohaven’s taldefgrobep alfa in spinal muscular atrophy (SMA) has missed its primary endpoint. The biotech plans to talk to the FDA about the next steps in SMA and is stepping up its interest in obesity on the strength of the data.